全文获取类型
收费全文 | 37416篇 |
免费 | 3272篇 |
国内免费 | 2293篇 |
专业分类
耳鼻咽喉 | 10篇 |
儿科学 | 190篇 |
妇产科学 | 29篇 |
基础医学 | 601篇 |
口腔科学 | 87篇 |
临床医学 | 942篇 |
内科学 | 1408篇 |
皮肤病学 | 65篇 |
神经病学 | 290篇 |
特种医学 | 788篇 |
外国民族医学 | 2篇 |
外科学 | 1095篇 |
综合类 | 4547篇 |
现状与发展 | 1篇 |
预防医学 | 995篇 |
眼科学 | 164篇 |
药学 | 21658篇 |
2篇 | |
中国医学 | 9961篇 |
肿瘤学 | 146篇 |
出版年
2024年 | 51篇 |
2023年 | 176篇 |
2022年 | 340篇 |
2021年 | 477篇 |
2020年 | 508篇 |
2019年 | 507篇 |
2018年 | 577篇 |
2017年 | 756篇 |
2016年 | 920篇 |
2015年 | 971篇 |
2014年 | 2182篇 |
2013年 | 2204篇 |
2012年 | 3127篇 |
2011年 | 3613篇 |
2010年 | 2876篇 |
2009年 | 2841篇 |
2008年 | 2949篇 |
2007年 | 3327篇 |
2006年 | 2914篇 |
2005年 | 2202篇 |
2004年 | 1691篇 |
2003年 | 1455篇 |
2002年 | 1097篇 |
2001年 | 861篇 |
2000年 | 664篇 |
1999年 | 497篇 |
1998年 | 361篇 |
1997年 | 341篇 |
1996年 | 287篇 |
1995年 | 262篇 |
1994年 | 262篇 |
1993年 | 156篇 |
1992年 | 195篇 |
1991年 | 155篇 |
1990年 | 145篇 |
1989年 | 150篇 |
1988年 | 98篇 |
1987年 | 95篇 |
1986年 | 56篇 |
1985年 | 124篇 |
1984年 | 138篇 |
1983年 | 106篇 |
1982年 | 74篇 |
1981年 | 51篇 |
1980年 | 33篇 |
1979年 | 21篇 |
1978年 | 23篇 |
1977年 | 19篇 |
1976年 | 17篇 |
1975年 | 11篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
《Nefrología : publicación oficial de la Sociedad Espa?ola Nefrologia》2022,42(5):578-584
IntroductionThere is no consensus on the most appropriate treatment for chronic active antibody-mediated rejection (cAMR). Recent studies suggest that treatment with tocilizumab (TCZ) may stabilize graft function, decrease the intensity of donor-specific HLA antibodies (DSAs) and reduce inflammation of microcirculation.Patients and methodsObservational study with renal allograft recipients diagnosed with cAMR (n = 5) who had not submitted a response to traditional treatment based on the combination of plasma replacements, immunoglobulins, and rituximab. Patients were told to be treated with TCZ as compassionate use in six doses per month (8 mg/kg/month). Renal function, proteinuria, and the intensity of DSAs were monitored during follow-up.ResultsFive patients, average age 60 ± 13 years, three male and two retrasplants (cPRA average 55%) with preformed DSAs. Treatment with TCZ was initiated within 47 ± 52 days of biopsy. In two cases treatment was discontinued after the first dose, by severe bicitopenia with cytomegalovirus viremia and by graft failure, respectively. In the three patients who completed treatment, no stability of renal function (serum creatinine from 1.73 ± 0.70 to 2.04 ± 0.52 mg/dL, e-FGR 4 6 ± 15 to 36 ± 16 mL/min), showed increased proteinuria (3.2 ± 4.0 to 6.9 ± 11.0 g/g) and the intensity of DSAs maintain stable. No changes were observed in the degree of inflammation of microcirculation (g + pt 4.2 ± 0.8 vs. 4.3 ± 1.0) or in the degree of transplant glomerulopathy (cg 1.2 ± 0.4 vs. 1.8 ± 1.0).ConclusionsTCZ therapy does not appear to be effective in modifying the natural history of chronic active antibody-mediated rejection, does not improve the degree of inflammation of microcirculation and does not reduces the intensity of DSAs. 相似文献
2.
3.
4.
《Journal of vascular and interventional radiology : JVIR》2022,33(4):399-407
PurposeTo evaluate the midterm outcomes of percutaneous transluminal renal angioplasty (PTRA) for pediatric renovascular hypertension (RVH).Materials and MethodsThe clinical data of patients who underwent PTRA for RVH in the authors’ hospital from 2012 to 2019 were retrospectively analyzed. Postprocedural blood pressure, glomerular filtration rate (GFR) of the affected kidney, restenosis, and complications were closely monitored.ResultsPTRA was performed in a total of 30 children (20 boys and 10 girls), with a mean age of 7.3 years ± 0.7 (range, 40 days to 13.9 years) and a mean weight of 25.0 kg ± 2.3 (range, 3.4–53 kg). The median follow-up period was 26.5 months (range, 1 month to 7.5 years). Technical success was achieved in 26 (86.7%) of the 30 patients. Restenosis developed in 3 patients (10.0%). Only 1 patient underwent stent implantation, and the stent fractured 8 months later, requiring further intervention. There were no other complications. In terms of clinical benefit of blood pressure control after the initial PTRA procedure, 15 patients (50%) were cured and 7 patients (23.3%) showed improvement. There was no significant difference in the etiology, lesion location, and lesion length between patients with clinical benefit and failure (P = .06, P = .202, and P = .06, respectively). GFR of the affected kidney was significantly improved from 19.9 mL/min ± 11.2 to 38.1 mL/min ± 11.9 at the 6-month follow-up after PTRA (P < .001).ConclusionsThe overall results of PTRA for pediatric RVH caused by different etiologies are promising. PTRA not only provided a clinical benefit of blood pressure control in 73.3% of the patients but also significantly improved the function of the affected kidney. 相似文献
5.
6.
目的:采用高效液相色谱-三重四级杆质谱(HPLC-MS/MS)测定清血八味片中的化学成分。方法:在负离子条件下采用Halo C_(18)色谱柱(2.1 mm×100 mm,2.7μm),以0.1%甲酸-10 mmol/L甲酸铵水和乙腈为流动相进行梯度洗脱,质谱采用Scan模式和MRM模式,检测清血八味片中的化学成分。结果:共鉴定出紫草中成分7种、土木香中成分3种、人工牛黄中成分4种、栀子中成分7种、瞿麦中成分7种、甘草中成分12种。结论:该方法快速可靠,操作简便,可用于清血八味片的质量控制研究,为临床药物使用提供一定的依据。 相似文献
7.
8.
9.
Lesley A. Inker Morgan E. Grams Andrew S. Levey Josef Coresh Massimo Cirillo John F. Collins Ron T. Gansevoort Orlando M. Gutierrez Takayuki Hamano Gunnar H. Heine Shizukiyo Ishikawa Sun Ha Jee Florian Kronenberg Martin J. Landray Katsuyuki Miura Girish N. Nadkarni Carmen A. Peralta Dietrich Rothenbacher Mark Woodward 《American journal of kidney diseases》2019,73(2):206-217
10.
Bimal Bhindi Christine M. Lohse Phillip J. Schulte Ross J. Mason John C. Cheville Stephen A. Boorjian Bradley C. Leibovich R. Houston Thompson 《European urology》2019,75(5):766-772